To further establish the feasibility and relevance of using plasma-derived EVs to monitor expression of GR and ENZA resistance, we studied a PDX MDA prostate cancer (PCa) 322-2-6a that is AR+/GR−. This evidence concerns the gene AR and prostate cancer.